Clinical Trial Update: Safety and Efficacy Study of First-line Treatment With QL1706 Plus Chemotherapy With or Without Bevacizumab in Women With Recurrent, or Metastatic Cervical Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update evaluating QL1706 plus chemotherapy with or without bevacizumab in first-line treatment for cervical cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• QL1706

Snippet

Sponsor: Qilu Pharmaceutical Co., Ltd. | Conditions: Cervical Cancer | Phase 2 | Status: UNKNOWN